Tirzepatide
SURPASS-T1D-1
Eli Lilly · Phase 3 · Active, not recruiting · Enrollment 905
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Tirzepatide Dose 1 | n/r | n/r | n/r | n/r |
| Tirzepatide Dose 2 | n/r | n/r | n/r | n/r |
| Tirzepatide Dose 3 | n/r | n/r | n/r | n/r |
| Tirzepatide Dose 4 | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- Tirzepatide Dose 1: endpoint not reported
- Tirzepatide Dose 2: endpoint not reported
- Tirzepatide Dose 3: endpoint not reported
- Tirzepatide Dose 4: endpoint not reported
- Placebo: endpoint not reported